Non-Alcoholic Steatohepatitis Market Size | Global Forecast 2028

report image

Non-Alcoholic Steatohepatitis (NASH) Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib & Cenicriviroc, and Others), Application (Treatment and Diagnosis), and Sales Channel (Hospital Pharmacy, Online Provider, and Retail Pharmacy)

Publication Month: Apr 2022 | Report Code: TIPRE00009653 | No. of Pages: 178 | Category: Pharmaceuticals | Status: Published

The non-alcoholic steatohepatitis (NASH) market is projected to reach US$ 24,266.81 million by 2028 from US$ 1,631.92 million in 2021; it is expected to register a CAGR of 47.1% from 2021 to 2028.

In nonalcoholic fatty liver disease (NAFLD), fat builds up in the liver. Non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) are types of NAFLD. When the fat buildup causes inflammation and damage, it leads to the development of NASH, which can lead to scarring of the liver. The scarring of the liver is a potentially life-threatening condition called cirrhosis.

The report offers insights and in-depth analysis of the non-alcoholic steatohepatitis (NASH) market emphasizing various parameters such as market trends, technological advancements, and market dynamics. It also provides the competitive landscape analysis of leading market players across the world. Furthermore, it includes the impact of the COVID-19 pandemic on the market across all the regions. The COVID-19 pandemic has disrupted the socioeconomic conditions of various countries across the world. In North America, the US was profoundly affected by the COVID-19 pandemic. Liver injury in the form of increased transaminases and hyperbilirubinemia among COVID-19 patients can be attributed to a couple of factors, including pre-existing liver disease. The comorbidity of nonalcoholic fatty liver disease (NAFLD) and NASH in these patients makes them prone to severe forms of liver injury. Given the high prevalence of NAFLD worldwide, it is far critical to recognize the results of COVID-19 in such patients, which include the role of comorbidities, disease progression, and COVID severity. The presence of fibrosis rather than NASH/NAFLD is associated with worse clinical outcomes and higher mortality in COVID-19 patients.

The impact of COVID-19 on comorbid patient populations, including people with diabetes, obesity, fatty liver disease, and NASH, has triggered the need of providing optimal care to patients. The Global Liver Institute is committed to operating with researchers and innovators worldwide to evaluate and inform a strong response to this pandemic rapidly. Research revolving around combating NAFLD and NASH indicates that the anticipated relationship with weight problems is stark. Therefore, a high incidence of NASH demands advanced diagnostics and treatments, which boosts research and development in the market. Thus, the COVID-19 crisis has fueled the non-alcoholic steatohepatitis (NASH) market growth.

  

Strategic Insights

Report Coverage - Non-Alcoholic Steatohepatitis (NASH) Market
Report CoverageDetails
Market Size Value inUS$ 1,631.92 million in 2021
Market Size Value byUS$ 24,266.81 million by 2028
Growth rateCAGR of 47.1% from 2021 to 2028.
Forecast Period2021- 2028
Base Year2021
No. of Pages178
No. of Tables86
No. of Charts & Figures77
Historical data availableYes
Segments coveredProduct, Application, and Sales Channel
Regional scopeNorth America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country scopeUS, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina
Report coverageRevenue forecast, company ranking, competitive landscape, growth factors, and trends
Free Sample Copy Available

Lucrative Regions for Non-Alcoholic Steatohepatitis (NASH) Market

Lucrative Regions for Non-Alcoholic Steatohepatitis (NASH) Market

Get more information on this report :


Market Insights

Increasing Initiatives for Boosting Awareness of NASH Drive Market Growth

NASH is an under-recognized condition. For a structured referral pathway and early detection, building greater awareness of this disease among the general public and primary care physicians (PCPs) is essential. By establishing a clear patient pathway for referrals and patient awareness campaigns, more individuals can be identified and sent to specialists for further evaluation. To raise awareness of NASH, the NASH Education Program launched the public education campaign on June 12, 2018, observed as the "International NASH Day," to raise awareness about the NAFLD and its more advanced form, NASH, which affects over ~115 million people.

NASH 24X7, a digital platform aimed at raising exposure and awareness regarding the NASH epidemic, took a few steps on the International NASH Day 2019 through HCP support, patient awareness, and press/TV release programs. To raise awareness on this day, NASH Crusaders of NASH 24X7 joined with top healthcare providers (HCPs), especially gastroenterologists and hepatologists, across India to hold many small and large-scale awareness & education workshops on liver health, highlighting the necessity of a healthy lifestyle in preventing NAFLD/NASH.

On the International NASH Day 2020, the American Liver Foundation joined a global community to raise awareness about NASH with support from the Allergan Foundation. American Liver Foundation (ALF) is now piloting a NASH Text Messaging Program, wherein people can sign up to receive weekly 3 messages for 10 weeks. Messages consist of hyperlinks to NASH resources, relevant facts, interactive quizzes, and sensible pointers for daily self-management. The ALF will open this system to the general public when the pilot is finished and evaluated. It collaborated with the Global Liver Institute (GLI) on the International NASH Day, and shared a few social media posts linked to GLI posts and the International NASH day page.

Thus, rising initiatives for the propelling the awareness regarding NASH are driving the non-alcoholic steatohepatitis (NASH) market.

Product-Based Insights

Based on product, the non-alcoholic steatohepatitis (NASH) market is segmented into vitamin E and pioglitazone, ocaliva, elafibranor, selonsertib & cenicriviroc, and others. In 2021, the others segment held the largest share of the market. The selonsertib & cenicriviroc segment is expected to register the fastest CAGR of 73.3% during the forecast period.

Organ Preservation Solutions Market, by Product – 2020 and 2028

Organ Preservation Solutions Market, by Product – 2020 and 2028

Get more information on this report :


Application-Based Insights

Based on application, the non-alcoholic steatohepatitis (NASH) market is bifurcated into treatment and diagnosis. In 2021, the treatment segment held a larger share of the market. However, the treatment segment is expected to register a higher CAGR of 47.3% during the forecast period.

Sales Channel-Based Insights

Based on sales channel, the non-alcoholic steatohepatitis (NASH) market is segmented into hospital pharmacy, retail pharmacy, and online provider. In 2021, the retail pharmacy segment held the largest share of the market. Moreover, the retail pharmacies segment is expected to report the highest CAGR of 47.2% during 2021–2028.

The non-alcoholic steatohepatitis (NASH) market players adopt organic strategies such as product launch and expansion to expand their footprint and product portfolio worldwide, as well as to meet the growing demands.

By

Geography

Based on geography, the non-alcoholic steatohepatitis (NASH) market is segmented as North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Company Profiles

  • Genfit SA
  • One Way Liver, S.L.
  • BioPredictive S.A.S.
  • Cadila Pharmaceuticals Ltd.
  • Prometheus Laboratories
  • Siemens Healthineers AG
  • Intercept Pharmaceuticals, Inc.
  • Novartis AG
  • Galmed Pharmaceuticals
  • Laboratory Corporation of America Holdings            

Frequently Asked Questions

Nonalcoholic fatty liver disease (NAFLD) is a condition in which fat builds up in your liver. Nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH) are types of NAFLD. Non-alcoholic steatohepatitis (NASH) is an advanced form of non-alcoholic fatty liver disease (NAFLD). NAFLD is caused by buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver. Scarring of the liver is a potentially life-threatening condition called cirrhosis.
Key factors that are driving the growth of this market are the rising prevalence of NASH and increasing initiatives for the awareness of NASH. Additionally, the growing clinical trials involving combination studies of drugs is likely to emerge as a significant future trend in the market during the forecast period.
The CAGR value of the non-alcoholic steatohepatitis (NASH) market during the forecasted period of 2021–2028 is 47.1%.
The product segment of the non-alcoholic steatohepatitis (NASH) market is segmented into vitamin E and pioglitazone, ocaliva, elafibranor, selonsertib & cenicriviroc, and others. In 2021, the others segment held the largest share of the market, by product. The selonsertib & cenicriviroc segment of the non-alcoholic steatohepatitis (NASH) market is expected to witness growth in its demand at the fastest CAGR of 73.3% from 2024 to 2028.
The treatment segment dominated the global non-alcoholic steatohepatitis (NASH) market and accounted for the largest market share of 84.90% in 2021.
The retail pharmacy segment dominated the global non-alcoholic steatohepatitis (NASH) market and accounted for the largest market share of 61.39% in 2021.
The non-alcoholic steatohepatitis (NASH) market majorly consists of players such as Genfit SA; One Way Liver, S.L.; BioPredictive S.A.S.; Cadila Pharmaceuticals Ltd.; Prometheus Laboratories; Siemens Healthineers AG; Intercept Pharmaceuticals, Inc.; Novartis AG; Galmed Pharmaceuticals; and Laboratory Corporation of America Holdings amongst others.
Intercept Pharmaceuticals, Inc and Genfit SA are the top two companies that hold huge market shares in the non-alcoholic steatohepatitis (NASH) market.
North America held the largest market share for non-alcoholic steatohepatitis in 2021. The United States held the largest market in North America for non-alcoholic steatohepatitis, and the market is expected to grow due to increasing adoption of technological advancements and rising emphasis on improving treatment outcomes are projected to accelerate the growth of the non-alcoholic steatohepatitis market.
The presence of nonalcoholic fatty liver disease (NAFLD) and NASH in patients with COVID-19 is likely to cause them to be prone to severe forms of liver injury. Given the high prevalence of NAFLD worldwide, it's far critical to recognize the results of COVID-19 in such patients, which include the role of comorbidities, disease progression, and the severity of COVID-19. The presence of fibrosis rather than NASH/NAFLD is associated with worse clinical outcomes and higher mortality in COVID-19 patients. Additionally, there seems to be an increased likelihood of liver injury in NAFLD patients with COVID-19.
NASH had the strongest association with COVID-19 of all comorbid metabolic conditions, including hypertension and obesity. As the world keeps confronting the novel coronavirus pandemic, the impact of COVID-19 on specific patient populations, which includes people with diabetes, obesity, fatty liver disease, and NASH, has proven the need of providing actionable recommendations to clinicians and patients to offer optimal care and avoid needless deaths. The Global Liver Institute is committed to operating with researchers and innovators worldwide to evaluate and inform a strong response to this pandemic rapidly. As the push to combat NAFLD and NASH continues, research indicates that the anticipated relationship with weight problems is stark. Individuals with signs and symptoms of underlying fatty liver disease and NASH are at higher risk and infectious for longer for COVID-19. Therefore, COVID-19 is affected positively on the growth of the market.
The List of Companies - Non-Alcoholic Steatohepatitis (NASH) Market
  1. Genfit SA
  2. One Way Liver, S.L.
  3. BioPredictive S.A.S
  4. Cadila Pharmaceuticals Ltd.
  5. Prometheus Laboratories
  6. Siemens Healthineers AG
  7. Intercept Pharmaceuticals, Inc.
  8. Novartis AG
  9. Galmed Pharmaceuticals
  10. Laboratory Corporation of America Holdings
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Non-Alcoholic Steatohepatitis market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global Non-Alcoholic Steatohepatitis market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution
TIPRE00009653
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market


Have a Question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak to Analyst
Pricing
  • $3000
  • $4550
  • $6550
  • $8550

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount